2022-12-02

Clinical Lab Products: The Future of Cervical Cancer Screening is Here

Molly Broache, Associate Director, Medical Affairs for US IDS discusses the future of cervical cancer screening

The future of cervical cancer screening is here. Featured in Clinical Lab Products, Associate Director of Medical Affairs Molly Broache notes that in today’s world where patients are catching up on missed screenings, adding pressure on already-pressured labs, it’s that much more important to take advantage of instruments and assays that do more and do better. The BD Onclarity HPV Assay is a perfect example with its cutting-edge approach to HPV testing.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

FiercePharma
New BD survey finds nearly half of women unaware of STI treatment options
Guidelines: ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
Cervical Cancer | Articles & Publications
Guidelines: ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors
BD Patient profile Tianna
Cervical Cancer | Brochures
HPV 31 Patient profile